Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451 on ClinicalTrials.gov · last registry update 2016-08-09

Finished June 2013, after enrolling 72 people. Primary outcome, as filed: Number of subjects with adverse events as a measure of safety and tolerability. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Hanmi Pharmaceutical Company Limited
Sponsor type: Industry
Enrollment: 72
Started: 2011-12
Primary completion: 2013-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of subjects with adverse events as a measure of safety and tolerability

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.